- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03727061
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
A Phase 1 Trial: Porfimer Sodium Mediated Interstitial Photodynamic for the Treatment of Patients With Locally Advanced or Recurrent Head and Neck Cancer
This phase I trial studies the side effects of interstitial photodynamic therapy (I-PDT) in treating patients with head and neck cancer that has spread to other parts of the body or that has come back. Interstitial photodynamic therapy uses a light-sensitive drug called porfimer sodium. This drug is activated by laser light delivered through special fibers into the tumor.
In this study the doctors will evaluate the safety of I-PDT and determine the potentially effective light setting in this treatment.
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the safety of porfimer sodium (Photofrin) mediated interstitial photodynamic therapy (I-PDT) in patients with locally advanced or recurrent head and neck cancer (HNC) .
- To determine the recommended light irradiance dose for a future Phase 2 trial of Photofrin® mediated I-PDT in patients with locally advanced or recurrent HNC
EXPLORATORY OBJECTIVES:
I . To access the objective tumor response rate
OUTLINE: This is a phase I study .
Patients receive porfimer sodium intravenously (IV) over 3-5 minutes and undergo I-PDT approximately 48 hours later.
After completion of study treatment, patients are followed up every 1-3 months for the first year, 2-6 months for 2nd year, and annually up to 5 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Kimberly Wooten, MD
- Phone Number: 716-845-4094
- Email: Kimberly.Wooten@roswellpark.org
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263-0001
- Recruiting
- Roswell Park Cancer Institute
-
Contact:
- ASK RPCI
- Phone Number: 877-275-7724
- Email: ASKRPCI@RoswellPark.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
- Patients with locally advanced or recurrent head and neck cancer who failed to respond to standard therapy and are not amenable to standard curative treatment.
- Tumor accessible for unrestricted illumination for interstitial photodynamic therapy (PDT) (accessibility as determined by the physician).
- Life expectancy of at least 6 months, in the judgment of the physician.
- Subjects of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
- Subject must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
Exclusion Criteria:
- High dose curative radiotherapy within 30 days in the area to be treated. Tumor invading a major blood vessel.
- Tumor is not measurable on a computed tomography (CT) or magnetic resonance imaging (MRI) scan according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Location and extension of the tumor precludes a potentially effective I-PDT.
- Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds.
- Platelet count < 75,000.
- Total serum bilirubin > 2 mg/dL
- Alkaline phosphatase (hepatic) > 3 times the upper normal limit
- Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) > 3 times the upper normal limit
- Patients with moderately to severely impaired creatinine clearance (crcl < 44) will be excluded.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant or nursing female subjects.
- Unwilling or unable to follow protocol requirements.
- Any condition which in the investigator's opinion deems the subject an unsuitable candidate to receive porfimer sodium
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A(porfimer sodium, I-PDT
Patients receive porfimer sodium IV over 3-5 minutes and undergo I-PDT approximately 48 hours later.
|
Given IV
Other Names:
Immunotherapy - Standard of care
Other Names:
Ancillary Studies
Undergo I-PDT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time Frame: Up to 30 days
|
The frequency of toxicities will be tabulated by grade across all dose levels and cycles.
All subjects who receive any study treatment will be considered evaluable for toxicity.
Sequential boundaries will be used to monitor the serious adverse event (SAE) rate.
|
Up to 30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kimberly Wooten, MD, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Head and Neck Neoplasms
- Carcinoma
- Recurrence
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Photosensitizing Agents
- Dermatologic Agents
- Immune Checkpoint Inhibitors
- Nivolumab
- Dihematoporphyrin Ether
- Trioxsalen
- Hematoporphyrin Derivative
Other Study ID Numbers
- I 67918
- R01CA193610 (U.S. NIH Grant/Contract)
- P01CA055791 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Head and Neck Carcinoma
-
Glenn J. HannaImmunityBio, Inc.RecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
Washington University School of MedicineEli Lilly and CompanyRecruitingRecurrent Head and Neck Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | HNSCC | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Head and Neck Carcinoma | Recurrent Skin Carcinoma | Recurrent Salivary Gland Carcinoma | Skin Squamous Cell CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingRecurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Pharyngeal Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma of Unknown Primary | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck CarcinomaUnited States
-
Nektar TherapeuticsMerck Sharp & Dohme LLC; SFJ Pharmaceuticals, Inc.TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States, Austria, Greece, Italy
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLCRecruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Resectable Head and Neck Squamous Cell CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell CarcinomaUnited States
-
PCI Biotech ASTerminatedRecurrent Head and Neck Cancer | Carcinoma, Squamous Cell of Head and NeckGermany, United Kingdom, France, Lithuania, Netherlands, Poland
-
BioNTech SERecruitingRecurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck CancerGermany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
Clinical Trials on Porfimer Sodium
-
Roswell Park Cancer InstituteCompletedEsophageal CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Roswell Park Cancer InstituteCompleted
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedPancreatic Cancer | Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct CancerUnited States
-
Concordia Laboratories Inc.CompletedNon-small Cell Lung Cancer (NSCLC) | Lung MetastasisUnited States, Canada
-
Concordia Laboratories Inc.Completed
-
University College, LondonCompletedGallbladder Cancer | Extrahepatic Bile Duct CancerUnited Kingdom
-
Harry T Whelan, MDPinnacle Biologics Inc.CompletedBrain Tumor, RecurrentUnited States
-
Roswell Park Cancer InstituteTerminated
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed